Chinese Antibody Society Post. "We highly recommend this insightful review article published three months ago with the title of “Six events that shaped antibody approvals in oncology”. The two authors of this paper are Suman Paul and Shibin Zhou at John Hopkins University and they focus on six monumental events that shaped antibody approvals over the last two and half decades."

https://www.linkedin.com/posts/chineseantibodysociety_antibodies-antibody-antibodytherapeutics-activity-7332004945795186688-N7B3/

The review highlights the major milestones that defined the development of antibody-based cancer therapies over the past 25 years. It discusses six landmark approvals, beginning with Rituximab and Trastuzumab, which established antibodies as transformative agents in both hematologic and solid tumors. Subsequent innovations such as antibody-drug conjugates, bispecific antibodies, and immune checkpoint inhibitors like Ipilimumab and Pembrolizumab expanded their reach to immune modulation and biomarker-driven treatment. These events emphasize the importance of sustained innovation, academic–industry collaboration, and emerging technologies like multispecific formats and novel delivery routes that will shape the future of antibody therapeutics in oncology.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1533796/full